Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate
- 1 September 2002
- Vol. 60 (3) , 115-121
- https://doi.org/10.1016/s0090-4295(02)01589-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient MiceScience, 1997
- Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivoBritish Journal of Dermatology, 1996
- Autocrine growth stimulation of human meningioma cells by platelet-derived growth factorJournal of Neurosurgery, 1996
- Induction of platelet‐derived growth factor A and B chains and over‐expression of their receptors in human pancreatic cancerInternational Journal of Cancer, 1995
- Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loopInternational Journal of Cancer, 1995
- Platelet–derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysisNeuropathology and Applied Neurobiology, 1994
- Platelet-derived growth factor expression and stimulation in human meningiomasJournal of Neurosurgery, 1994
- The multistep nature of cancerTrends in Genetics, 1993